Table 3.
Pharmacological treatment and participation in exercise training reported at the 12–14-month visit
| Traditional care | Tailored nurse-led care | P-value | |
|---|---|---|---|
| Pharmacological treatment: | |||
| • Platelet inhibitors | n = 93, 89% | n = 102, 91% | 0.54 |
| • Statins | n = 92, 88% | n = 102, 91% | 0.41 |
| • Ezetimibe | n = 11, 10% | n = 23, 21% | 0.04 |
| • ACEi or ARB | n = 91, 87% | n = 96, 86% | 0.84 |
| • Β-blocker | n = 78, 74% | n = 85, 76% | 0.98 |
| Participation in exercise training | n = 64, 61% | n = 83, 74% | 0.04 |
Numbers presented as numbers (n) and percentages (%)and p-values for difference
ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker